1. Antidepressiva tijdens de zwangerschap en het gebruik van luchtwegmedicatie door de nakomelingen
- Subjects
lung disease ,breathing ,effect size ,disease association ,tricyclic antidepressant agent ,article ,first trimester pregnancy ,prenatal drug exposure ,respiratory system ,sample size ,lung surfactant ,serotonin uptake inhibitor ,maternal smoking ,controlled study ,human - Abstract
OBJECTIVE: To compare the use of drugs for pulmonary diseases in children who were exposed to antidepressants in utero with non-exposed children. Some studies suggest an association between in utero exposure to antidepressants and the occurrence of pulmonary diseases later in life. Antidepressants are thought to be involved in the development of the respiratory rhythm generator and the maturation of surfactant formation. DESIGN AND METHODS: The pharmacy prescription database IADB.nl was used for a cohort study. The use of drugs for pulmonary diseases in children after in utero exposure to antidepressants was compared to children with no antidepressant exposure in utero. Drugs for pulmonary diseases were applied as a proxy for disturbed development of the respiratory tract. RESULTS: A small but significant increase in the incidence risk ratio (IRR) of the use of drugs for pulmonary diseases was found after anytime in utero exposure to serotonin reuptake inhibitors (SSRIs) (1.17; CI951.16-1.18). IRR also was increased for specific use of SSRIs in the first trimester (1.18; CI951.17-1.20). IRR increase for children who were exposed to tricyclic antidepressants was not statistically significant. As sample size was rather small in both groups, the effect size is modest and may also be confounded by maternal smoking. CONCLUSIONS: Children exposed to SSRIs in utero use significantly more drugs for pulmonary diseases, especially when exposure occurred during the first trimester of pregnancy. However, the increased use of such drugs may also be related to other factors.
- Published
- 2013